ClinicalTrials.gg
CompletedNCT00950950Updated Jul 5, 2019Results posted

A Study to Evaluate the Effect of Romosozumab (AMG 785) on Bone Quality of the Forearm in Postmenopausal Women With Low Bone Mass

A Phase 1 interventional study of Romosozumab and Placebo in Osteopenia, sponsored by Amgen. Completed. Open to female participants aged 55 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-05.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
55 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing romosozumab in Bone Diseases, Metabolic — none open to participants now, 1 under way, none of them phase 3. romosozumab · Bone Diseases, Metabolic.

Enrollment
10th of 11
24 · median 74
Started
2009
with 1 other
Phase 1
4 of 11
none open now
Registered
2nd of 11
by date
Lead sponsor
9 of 11
Amgen

Among the 11 studies testing romosozumab in Bone Diseases, Metabolic, this one is the 10th largest by enrollment, is one of 2 that started in 2009, is one of 4 in phase 1, and was the 2nd registered.

Bone Diseases, Metabolic

662 studies on the registry are indexed under Bone Diseases, Metabolic; 94 are open to participants now.

Browse Bone Diseases, Metabolic studies →

Open to participants now

None of the 11 studies testing romosozumab in Bone Diseases, Metabolic is open now. The open studies under Bone Diseases, Metabolic, anywhere →

About romosozumab

romosozumab: first FDA approval 2019 (EVENITY), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 64 Bone Diseases, Metabolic studies recruiting now, 28 (44%) set no upper age limit and 28 (44%) stop at 75 or younger; 12 take children under 18; 22 take healthy volunteers.

This study: 55 Years to 80 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing romosozumab in Bone Diseases, Metabolic as a file.
02

Study summary

The purpose of this study is to evaluate the effect of romosozumab on parameters of bone quality of the forearm using peripheral quantitative computed tomography (pQCT) following multiple subcutaneous dose administrations of romosozumab in postmenopausal women with low bone mass.

03

Conditions studied

  • Osteopenia

Keywords

  • Amgen
  • Postmenopausal
  • Bone Density
04

Who can participate

Ages eligible
55 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy females between 55 to 80 years of age
  • females (based on medical history) defined as 12 continuous months of spontaneous amenorrhea

    • Women 60 years of age and older will be considered postmenopausal
    • Women 55-59 must have a serum follicle-stimulating hormone result > 40 mIU/mL and serum estradiol ≤ 20 pg/mL
  • Low bone mineral density (BMD), defined as a BMD T-score between -1.0 and -2.5 at the lumbar spine (L1-L4) and/or femoral neck
  • Weight ≤ 98 kg (216 lb) and/or height ≤ 196 cm (77 in)
  • 25-hydroxyvitamin D ≥ 20 ng/mL at screening
  • Willing and able to take ≥ 500 mg calcium and ≥ 400 IU (but ≤ 1,000 IU) vitamin D daily

Exclusion criteria

Exclusion Criteria:

  • Osteoporosis, defined as a BMD T-score ≤ -2.5 at the lumbar spine or femoral neck
  • History of vertebral fracture, or fragility fracture of the wrist, humerus, hip or pelvis
  • Diagnosed with any condition that will affect bone metabolism
  • Subjects with fewer than 2 evaluable vertebrae; metal in forearms bilaterally that would not allow for at least one evaluable forearm
  • Administration of the following medications within 6 months before study drug administration. This includes all routes of administration, for example intranasal and topical skin patches, unless otherwise noted:

    • Hormone replacement therapy [(eg, estrogen, estrogen-like compounds such as raloxifene). Infrequent use of estrogen vaginal creams (\< 3 times per week) is allowed.]
    • Calcitonin
    • Parathyroid hormone (or any derivative)
    • Glucocorticosteroids (inhaled or topical administered more than 2 weeks before the enrollment date are allowed)
    • Anabolic steroids
    • Calcitriol, and available analogues
  • Administration of daily, weekly, or monthly bisphosphonates (BP) unless meeting the following criteria:

    • \< 2 weeks of BP use requires a 2-month
    • 2 weeks to 3 months of BP use requires a 9-month washout period
    • 3 to 6 months of BP use requires a 1-year washout period
    • > 6 months of BP use requires a 3-year washout period;
  • Greatly differing levels of physical activity or constant levels of intense physical exercise during the 6 months before study drug administration
  • Known sensitivity to mammalian-derived drug preparations
  • Known to be surface antigen, virus or (HIV) positive or a known diagnosis of acquired immunodeficiency syndrome (AIDS)
  • Any organic or psychiatric disorder, which, in the opinion of the investigator, poses a risk to subject safety and may prevent the subject from completing the study or interfere with the interpretation of the study results
  • Unavailable for follow-up assessment or any concerns for subject's compliance with the protocol procedures
  • Any other condition that might reduce the chance of obtaining data required by the protocol or that might compromise the ability to give truly
  • History or evidence of a disorder, condition or disease that, in the opinion of the Investigator or Amgen physician would pose a risk to subject safety or interfere with the study evaluation, procedures or completion
  • Clinically significant abnormality during the screening physical examination, (ECG) or laboratory evaluation
  • Participation in another clinical study within 4 weeks of screening or within 5 times the half-life of the agent in the other clinical study, if known
  • Has donated or lost 400 mL or more of blood or plasma within 8 weeks of study drug administration
  • Previous AMG 785 exposure
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants were randomized to receive matching placebo administered by subcutaneous injection once every 4 weeks (Q4W) for 3 months.

    Drug: Placebo

  • Experimental
    Romosozumab

    Participants were randomized to receive 3 mg/kg romosozumab administered by subcutaneous injection once every 4 weeks (Q4W) for 3 months.

    Drug: Romosozumab

Interventions

  • Administered by subcutaneous injection

    Also known as: AMG 785, EVENITY™

  • DrugPlacebo

    Administered by subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Polar Cross-sectional Moment of Inertia at the Distal Radius

    The polar moment of inertia is a geometric measurement used to predict bone quality, specifically the ability to resist torsion (twisting), and is highly correlated with fracture load at the distal radius. The polar cross-sectional moment of inertia was assessed using peripheral quantitative computed tomography (pQCT), a 3-dimensional imaging technology which can be used for volumetric analysis of appendicular skeletal sites such as the arms and the legs. The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.

    Time frame: Baseline and days 29, 57, 85, 127, and 169

Secondary outcomes

  1. Percent Change From Baseline in Total Bone Area at the Distal Radius

    Total bone area was assessed using peripheral quantitative computed tomography (pQCT), a 3-dimensional imaging technology which can be used for volumetric analysis of appendicular skeletal sites such as the arms and the legs. The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.

    Time frame: Baseline and days 29, 57, 85, 127, and 169

  2. Percent Change From Baseline in Total Bone Mineral Content at the Distal Radius

    Total bone mineral content was assessed using peripheral quantitative computed tomography (pQCT). The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.

    Time frame: Baseline and days 29, 57, 85, 127, and 169

  3. Percent Change From Baseline in Total Bone Mineral Density at the Distal Radius

    Total bone mineral density was assessed using peripheral quantitative computed tomography (pQCT). The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.

    Time frame: Baseline and days 29, 57, 85, 127, and 169

  4. Percent Change From Baseline in Cortical Bone Area at the Distal Radius

    Cortical bone area was assessed using peripheral quantitative computed tomography (pQCT). The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.

    Time frame: Baseline and days 29, 57, 85, 127, and 169

  5. Percent Change From Baseline in Cortical Bone Mineral Content at the Distal Radius

    Cortical bone mineral content was assessed using peripheral quantitative computed tomography (pQCT). The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.

    Time frame: Baseline and days 29, 57, 85, 127, and 169

  6. Percent Change From Baseline in Cortical Bone Mineral Density at the Distal Radius

    Cortical bone mineral density was assessed using peripheral quantitative computed tomography (pQCT). The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.

    Time frame: Baseline and days 29, 57, 85, 127, and 169

  7. Percent Change From Baseline in Endocortical Circumference at the Distal Radius

    Endocortical circumference was derived from pQCT measurements based on applying a circular ring model to the cortical shell. The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.

    Time frame: Baseline and days 29, 57, 85, 127, and 169

  8. Percent Change From Baseline in Periosteal Circumference at the Distal Radius

    Periosteal circumference was derived from pQCT measurements based on applying a circular ring model to the cortical shell. The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.

    Time frame: Baseline and days 29, 57, 85, 127, and 169

  9. Percent Change From Baseline in Cortical Thickness at the Distal Radius

    Cortical thickness was derived from pQCT measurements based on applying a circular ring model to the cortical shell. The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.

    Time frame: Baseline and days 29, 57, 85, 127, and 169

  10. Percent Change From Baseline in Polar Section Modulus at the Distal Radius

    Polar section modulus is a measurement of bone strength and was derived from pQCT measurements. The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.

    Time frame: Baseline and days 29, 57, 85, 127, and 169

  11. Percent Change From Baseline in Polar Strength Strain Index at the Distal Radius

    The polar strength strain index is a measurement of bone strength and was derived from pQCT measurements. The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.

    Time frame: Baseline and days 29, 57, 85, 127, and 169

  12. Percent Change From Baseline in Axial Moment of Inertia at the Distal Radius

    Axial moment of inertia is an indicator of the ability of bone to resist bending, and was derived from pQCT measurements based on a circular ring model. The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.

    Time frame: Baseline and days 29, 57, 85, 127, and 169

  13. Percent Change From Baseline in Total Bone Area at the Ultradistal Radius

    Total bone area was assessed using peripheral quantitative computed tomography (pQCT), a 3-dimensional imaging technology which can be used for volumetric analysis of appendicular skeletal sites such as the arms and the legs. The ultradistal slice was acquired at 4% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.

    Time frame: Baseline and days 29, 57, 85, 127, and 169

  14. Percent Change From Baseline in Total Bone Mineral Content at the Ultradistal Radius

    Total bone mineral content was assessed using peripheral quantitative computed tomography (pQCT). The ultradistal slice was acquired at 4% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.

    Time frame: Baseline and days 29, 57, 85, 127, and 169

  15. Percent Change From Baseline in Total Bone Mineral Density at the Ultradistal Radius

    Total bone mineral density was assessed using peripheral quantitative computed tomography (pQCT). The ultradistal slice was acquired at 4% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.

    Time frame: Baseline and days 29, 57, 85, 127, and 169

  16. Percent Change From Baseline in Trabecular Bone Area at the Ultradistal Radius

    Trabecular bone area was assessed using peripheral quantitative computed tomography (pQCT). The ultradistal slice was acquired at 4% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.

    Time frame: Baseline and days 29, 57, 85, 127, and 169

  17. Percent Change From Baseline in Trabecular Bone Mineral Content at the Ultradistal Radius

    Trabecular bone mineral content was assessed using peripheral quantitative computed tomography (pQCT). The ultradistal slice was acquired at 4% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.

    Time frame: Baseline and days 29, 57, 85, 127, and 169

  18. Percent Change From Baseline in Trabecular Bone Mineral Density at the Ultradistal Radius

    Trabecular bone mineral density was assessed using peripheral quantitative computed tomography (pQCT). The ultradistal slice was acquired at 4% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.

    Time frame: Baseline and days 29, 57, 85, 127, and 169

  19. Percent Change From Baseline in Polar Strength Strain Index at the Ultradistal Radius

    The polar strength strain index is a measurement of bone strength and was derived from pQCT measurements. The ultradistal slice was acquired at 4% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.

    Time frame: Baseline and days 29, 57, 85, 127, and 169

  20. Percent Change From Baseline in Bone Mineral Density at the One-third Radius

    Bone mineral density was assessed using dual energy x-ray absorptiometry (DXA). Scans were analyzed by a central reader.

    Time frame: Baseline and days 29, 57, 85, 127, and 169

  21. Percent Change From Baseline in Bone Mineral Density at the Total Wrist

    Bone mineral density was assessed using dual energy x-ray absorptiometry (DXA). Scans were analyzed by a central reader.

    Time frame: Baseline and days 29, 57, 85, 127, and 169

  22. Percent Change From Baseline in Bone Mineral Density at the Total Lumbar Spine

    Bone mineral density was assessed using dual energy x-ray absorptiometry (DXA). Scans were analyzed by a central reader.

    Time frame: Baseline and days 85 and 169

  23. Percent Change From Baseline in Serum Procollagen Type 1 N-terminal Propeptide (P1NP)

    Time frame: Baseline and days 4, 15, 29, 57, 62, 71, 85, 99, 127, and 169

  24. Percent Change From Baseline in Serum C-Telopeptide (sCTX)

    Time frame: Baseline and days 4, 15, 29, 57, 62, 71, 85, 99, 127, and 169

  25. Time to Maximum Serum Concentration (Tmax) of Romosozumab

    Serum concentrations of romosozumab were measured by a validated enzyme-linked immunosorbent assay. The lower limit of quantification (LLOQ) was 50 ng/mL.

    Time frame: First Dose: Day 1 (predose) and on days 4, 15, and 29 (predose). Last Dose: Days 57 (predose), 62, 71, 85, 99, 127, and 169

  26. Maximum Serum Concentration (Cmax) of Romosozumab

    Serum concentrations of romosozumab were measured by a validated enzyme-linked immunosorbent assay. The lower limit of quantification (LLOQ) was 50 ng/mL.

    Time frame: First Dose: Day 1 (predose) and on days 4, 15, and 29 (predose). Last Dose: Days 57 (predose), 62, 71, 85, 99, 127, and 169

  27. Area Under the Serum Concentration-time Curve From Time 0 to Tau (AUC0-28)

    Serum concentrations of romosozumab were measured by a validated enzyme-linked immunosorbent assay. The lower limit of quantification (LLOQ) was 50 ng/mL. The area under the serum drug concentration-time curve from time zero to tau (tau = 28 days) (AUC0-28) was calculated by the linear trapezoidal method.

    Time frame: First Dose: Day 1 (predose) and on days 4, 15, and 29 (predose). Last Dose: Days 57 (predose), 62, 71, 85, 99, 127, and 169

  28. Area Under the Serum Concentration-time Curve From Time 0 to Infinity (AUCinf)

    Serum concentrations of romosozumab were measured by a validated enzyme-linked immunosorbent assay. The lower limit of quantification (LLOQ) was 50 ng/mL.

    Time frame: Last Dose: Days 57 (predose), 62, 71, 85, 99, 127, and 169

  29. Apparent Clearance (CL/F) of Romosozumab

    Serum concentrations of romosozumab were measured by a validated enzyme-linked immunosorbent assay. The lower limit of quantification (LLOQ) was 50 ng/mL.

    Time frame: Last Dose: Days 57 (predose), 62, 71, 85, 99, 127, and 169

  30. Terminal Half-life (t1/2,z) of Romosozumab

    Serum concentrations of romosozumab were measured by a validated enzyme-linked immunosorbent assay. The lower limit of quantification (LLOQ) was 50 ng/mL.

    Time frame: Last Dose: Days 57 (predose), 62, 71, 85, 99, 127, and 169

  31. Accumulation Ratio

    Accumulation ratio was calculated as the ratio of AUC0-28 after the last dose to AUC0-28 after the first dose.

    Time frame: First Dose: Day 1 (predose) and on days 4, 15, and 29 (predose). Last Dose: Days 57 (predose), 62, 71, 85, 99, 127, and 169

07

Results

Posted Jul 5, 2019

Participant flow

This study was conducted at a single center in the United States.

Participant flow — Overall Study
MilestonePlaceboRomosozumab
Started1212
Completed1111
Not completed11
Withdrew: Adverse event10
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryPercent Change From Baseline in Polar Cross-sectional Moment of Inertia at the Distal Radius

The polar moment of inertia is a geometric measurement used to predict bone quality, specifically the ability to resist torsion (twisting), and is highly correlated with fracture load at the distal radius. The polar cross-sectional moment of inertia was assessed using peripheral quantitative computed tomography (pQCT), a 3-dimensional imaging technology which can be used for volumetric analysis of appendicular skeletal sites such as the arms and the legs. The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.

Time frame:
Baseline and days 29, 57, 85, 127, and 169
Reported as:
Mean · percent change
Percent Change From Baseline in Polar Cross-sectional Moment of Inertia at the Distal Radius
percent changePlaceboRomosozumab
Day 29-1.16 ± 1.400.16 ± 0.95
Day 57-1.03 ± 1.00-1.03 ± 1.19
Day 85-2.28 ± 1.211.45 ± 1.03
Day 127-1.93 ± 1.220.87 ± 0.89
Day 169-1.66 ± 1.22-0.08 ± 1.12
SecondaryPercent Change From Baseline in Total Bone Area at the Distal Radius

Total bone area was assessed using peripheral quantitative computed tomography (pQCT), a 3-dimensional imaging technology which can be used for volumetric analysis of appendicular skeletal sites such as the arms and the legs. The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.

Time frame:
Baseline and days 29, 57, 85, 127, and 169
Reported as:
Mean · percent change
Percent Change From Baseline in Total Bone Area at the Distal Radius
percent changePlaceboRomosozumab
Day 29-0.07 ± 0.56-0.21 ± 0.40
Day 57-0.08 ± 0.48-0.13 ± 0.56
Day 85-0.79 ± 0.490.38 ± 0.61
Day 1270.05 ± 0.430.87 ± 0.66
Day 169-0.23 ± 0.46-0.04 ± 0.70
SecondaryPercent Change From Baseline in Total Bone Mineral Content at the Distal Radius

Total bone mineral content was assessed using peripheral quantitative computed tomography (pQCT). The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.

Time frame:
Baseline and days 29, 57, 85, 127, and 169
Reported as:
Mean · percent change
Percent Change From Baseline in Total Bone Mineral Content at the Distal Radius
percent changePlaceboRomosozumab
Day 29-0.39 ± 0.40-0.27 ± 0.41
Day 57-0.33 ± 0.37-0.49 ± 0.27
Day 85-0.86 ± 0.47-0.51 ± 0.36
Day 127-0.66 ± 0.36-0.43 ± 0.37
Day 169-1.34 ± 0.30-1.09 ± 0.36
SecondaryPercent Change From Baseline in Total Bone Mineral Density at the Distal Radius

Total bone mineral density was assessed using peripheral quantitative computed tomography (pQCT). The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.

Time frame:
Baseline and days 29, 57, 85, 127, and 169
Reported as:
Mean · percent change
Percent Change From Baseline in Total Bone Mineral Density at the Distal Radius
percent changePlaceboRomosozumab
Day 29-0.30 ± 0.48-0.06 ± 0.30
Day 57-0.24 ± 0.38-0.34 ± 0.44
Day 85-0.07 ± 0.19-0.86 ± 0.53
Day 127-0.69 ± 0.48-1.26 ± 0.53
Day 169-0.10 ± 0.42-1.02 ± 0.55
SecondaryPercent Change From Baseline in Cortical Bone Area at the Distal Radius

Cortical bone area was assessed using peripheral quantitative computed tomography (pQCT). The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.

Time frame:
Baseline and days 29, 57, 85, 127, and 169
Reported as:
Mean · percent change
Percent Change From Baseline in Cortical Bone Area at the Distal Radius
percent changePlaceboRomosozumab
Day 29-0.27 ± 0.580.06 ± 0.63
Day 57-0.05 ± 0.54-0.53 ± 0.64
Day 85-1.39 ± 0.770.69 ± 0.67
Day 127-1.41 ± 0.810.28 ± 0.63
Day 169-1.59 ± 0.58-0.50 ± 0.74
SecondaryPercent Change From Baseline in Cortical Bone Mineral Content at the Distal Radius

Cortical bone mineral content was assessed using peripheral quantitative computed tomography (pQCT). The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.

Time frame:
Baseline and days 29, 57, 85, 127, and 169
Reported as:
Mean · percent change
Percent Change From Baseline in Cortical Bone Mineral Content at the Distal Radius
percent changePlaceboRomosozumab
Day 29-0.33 ± 0.570.07 ± 0.46
Day 57-0.29 ± 0.52-0.86 ± 0.45
Day 85-1.08 ± 0.66-0.07 ± 0.66
Day 127-1.45 ± 0.82-0.66 ± 0.57
Day 169-1.69 ± 0.55-1.29 ± 0.67
SecondaryPercent Change From Baseline in Cortical Bone Mineral Density at the Distal Radius

Cortical bone mineral density was assessed using peripheral quantitative computed tomography (pQCT). The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.

Time frame:
Baseline and days 29, 57, 85, 127, and 169
Reported as:
Mean · percent change
Percent Change From Baseline in Cortical Bone Mineral Density at the Distal Radius
percent changePlaceboRomosozumab
Day 29-0.06 ± 0.100.02 ± 0.21
Day 57-0.24 ± 0.21-0.32 ± 0.28
Day 850.32 ± 0.24-0.76 ± 0.23
Day 127-0.04 ± 0.23-0.92 ± 0.40
Day 169-0.10 ± 0.23-0.79 ± 0.31
SecondaryPercent Change From Baseline in Endocortical Circumference at the Distal Radius

Endocortical circumference was derived from pQCT measurements based on applying a circular ring model to the cortical shell. The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.

Time frame:
Baseline and days 29, 57, 85, 127, and 169
Reported as:
Mean · percent change
Percent Change From Baseline in Endocortical Circumference at the Distal Radius
percent changePlaceboRomosozumab
Day 290.20 ± 0.74-0.19 ± 0.50
Day 57-0.23 ± 0.730.26 ± 0.67
Day 85-0.03 ± 0.39-0.07 ± 0.72
Day 1270.77 ± 0.800.89 ± 0.66
Day 1690.85 ± 0.660.49 ± 0.84
SecondaryPercent Change From Baseline in Periosteal Circumference at the Distal Radius

Periosteal circumference was derived from pQCT measurements based on applying a circular ring model to the cortical shell. The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.

Time frame:
Baseline and days 29, 57, 85, 127, and 169
Reported as:
Mean · percent change
Percent Change From Baseline in Periosteal Circumference at the Distal Radius
percent changePlaceboRomosozumab
Day 29-0.04 ± 0.28-0.11 ± 0.20
Day 57-0.04 ± 0.24-0.07 ± 0.28
Day 85-0.40 ± 0.250.19 ± 0.31
Day 1270.02 ± 0.220.43 ± 0.33
Day 169-0.12 ± 0.23-0.02 ± 0.35
SecondaryPercent Change From Baseline in Cortical Thickness at the Distal Radius

Cortical thickness was derived from pQCT measurements based on applying a circular ring model to the cortical shell. The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.

Time frame:
Baseline and days 29, 57, 85, 127, and 169
Reported as:
Mean · percent change
Percent Change From Baseline in Cortical Thickness at the Distal Radius
percent changePlaceboRomosozumab
Day 29-0.29 ± 0.820.22 ± 0.77
Day 570.09 ± 0.79-0.56 ± 0.85
Day 85-1.14 ± 0.720.64 ± 0.99
Day 127-1.69 ± 1.14-0.31 ± 0.80
Day 169-1.82 ± 0.78-0.62 ± 1.09
SecondaryPercent Change From Baseline in Polar Section Modulus at the Distal Radius

Polar section modulus is a measurement of bone strength and was derived from pQCT measurements. The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.

Time frame:
Baseline and days 29, 57, 85, 127, and 169
Reported as:
Mean · percent change
Percent Change From Baseline in Polar Section Modulus at the Distal Radius
percent changePlaceboRomosozumab
Day 290.18 ± 0.780.02 ± 0.78
Day 57-0.11 ± 1.08-0.46 ± 1.05
Day 85-2.14 ± 1.400.93 ± 1.22
Day 127-2.31 ± 1.551.76 ± 1.32
Day 169-1.67 ± 1.14-1.05 ± 1.20
SecondaryPercent Change From Baseline in Polar Strength Strain Index at the Distal Radius

The polar strength strain index is a measurement of bone strength and was derived from pQCT measurements. The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.

Time frame:
Baseline and days 29, 57, 85, 127, and 169
Reported as:
Mean · percent change
Percent Change From Baseline in Polar Strength Strain Index at the Distal Radius
percent changePlaceboRomosozumab
Day 29-1.85 ± 0.81-0.78 ± 0.51
Day 57-1.32 ± 0.75-1.47 ± 1.21
Day 850.36 ± 0.99-1.91 ± 1.49
Day 127-0.71 ± 0.95-1.57 ± 0.94
Day 169-0.41 ± 0.98-1.25 ± 0.78
SecondaryPercent Change From Baseline in Axial Moment of Inertia at the Distal Radius

Axial moment of inertia is an indicator of the ability of bone to resist bending, and was derived from pQCT measurements based on a circular ring model. The distal slice was acquired at 20% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.

Time frame:
Baseline and days 29, 57, 85, 127, and 169
Reported as:
Mean · percent change
Percent Change From Baseline in Axial Moment of Inertia at the Distal Radius
percent changePlaceboRomosozumab
Day 29-0.22 ± 0.91-0.23 ± 0.73
Day 57-0.19 ± 0.74-0.49 ± 0.88
Day 85-1.90 ± 1.090.94 ± 0.83
Day 127-0.90 ± 0.651.41 ± 1.04
Day 169-1.25 ± 0.75-0.28 ± 0.98
SecondaryPercent Change From Baseline in Total Bone Area at the Ultradistal Radius

Total bone area was assessed using peripheral quantitative computed tomography (pQCT), a 3-dimensional imaging technology which can be used for volumetric analysis of appendicular skeletal sites such as the arms and the legs. The ultradistal slice was acquired at 4% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.

Time frame:
Baseline and days 29, 57, 85, 127, and 169
Reported as:
Mean · percent change
Percent Change From Baseline in Total Bone Area at the Ultradistal Radius
percent changePlaceboRomosozumab
Day 29-2.30 ± 3.64-0.72 ± 2.35
Day 57-5.11 ± 2.44-0.01 ± 3.66
Day 85-0.27 ± 2.377.35 ± 3.21
Day 127-0.43 ± 2.463.27 ± 2.96
Day 1691.90 ± 2.500.91 ± 3.32
SecondaryPercent Change From Baseline in Total Bone Mineral Content at the Ultradistal Radius

Total bone mineral content was assessed using peripheral quantitative computed tomography (pQCT). The ultradistal slice was acquired at 4% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.

Time frame:
Baseline and days 29, 57, 85, 127, and 169
Reported as:
Mean · percent change
Percent Change From Baseline in Total Bone Mineral Content at the Ultradistal Radius
percent changePlaceboRomosozumab
Day 290.63 ± 0.43-0.30 ± 0.70
Day 570.13 ± 0.53-0.09 ± 0.63
Day 850.63 ± 0.561.16 ± 0.39
Day 1270.46 ± 0.56-0.14 ± 0.46
Day 1690.15 ± 0.59-0.64 ± 0.97
SecondaryPercent Change From Baseline in Total Bone Mineral Density at the Ultradistal Radius

Total bone mineral density was assessed using peripheral quantitative computed tomography (pQCT). The ultradistal slice was acquired at 4% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.

Time frame:
Baseline and days 29, 57, 85, 127, and 169
Reported as:
Mean · percent change
Percent Change From Baseline in Total Bone Mineral Density at the Ultradistal Radius
percent changePlaceboRomosozumab
Day 294.45 ± 4.420.91 ± 1.97
Day 576.22 ± 3.191.19 ± 2.98
Day 851.52 ± 2.64-4.95 ± 2.33
Day 1271.43 ± 2.35-2.53 ± 2.38
Day 169-1.14 ± 2.72-0.81 ± 2.59
SecondaryPercent Change From Baseline in Trabecular Bone Area at the Ultradistal Radius

Trabecular bone area was assessed using peripheral quantitative computed tomography (pQCT). The ultradistal slice was acquired at 4% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.

Time frame:
Baseline and days 29, 57, 85, 127, and 169
Reported as:
Mean · percent change
Percent Change From Baseline in Trabecular Bone Area at the Ultradistal Radius
percent changePlaceboRomosozumab
Day 29-3.54 ± 5.68-0.64 ± 3.59
Day 57-8.06 ± 3.860.43 ± 6.21
Day 85-0.55 ± 3.8212.00 ± 5.84
Day 127-1.86 ± 4.015.60 ± 5.22
Day 1692.84 ± 4.181.57 ± 5.20
SecondaryPercent Change From Baseline in Trabecular Bone Mineral Content at the Ultradistal Radius

Trabecular bone mineral content was assessed using peripheral quantitative computed tomography (pQCT). The ultradistal slice was acquired at 4% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.

Time frame:
Baseline and days 29, 57, 85, 127, and 169
Reported as:
Mean · percent change
Percent Change From Baseline in Trabecular Bone Mineral Content at the Ultradistal Radius
percent changePlaceboRomosozumab
Day 29-3.26 ± 7.35-0.52 ± 4.78
Day 57-9.52 ± 4.680.02 ± 7.61
Day 851.02 ± 5.5114.64 ± 7.06
Day 127-0.70 ± 6.155.68 ± 6.54
Day 1695.12 ± 5.551.74 ± 6.71
SecondaryPercent Change From Baseline in Trabecular Bone Mineral Density at the Ultradistal Radius

Trabecular bone mineral density was assessed using peripheral quantitative computed tomography (pQCT). The ultradistal slice was acquired at 4% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.

Time frame:
Baseline and days 29, 57, 85, 127, and 169
Reported as:
Mean · percent change
Percent Change From Baseline in Trabecular Bone Mineral Density at the Ultradistal Radius
percent changePlaceboRomosozumab
Day 29-0.78 ± 1.88-0.34 ± 1.33
Day 57-1.98 ± 1.16-1.30 ± 1.59
Day 850.98 ± 1.642.00 ± 0.88
Day 1270.53 ± 1.92-0.49 ± 1.19
Day 1691.74 ± 1.47-0.51 ± 1.64
SecondaryPercent Change From Baseline in Polar Strength Strain Index at the Ultradistal Radius

The polar strength strain index is a measurement of bone strength and was derived from pQCT measurements. The ultradistal slice was acquired at 4% of the length of the ulna proximal to the radial endplate. Scans were analyzed by a central reader.

Time frame:
Baseline and days 29, 57, 85, 127, and 169
Reported as:
Mean · percent change
Percent Change From Baseline in Polar Strength Strain Index at the Ultradistal Radius
percent changePlaceboRomosozumab
Day 292.69 ± 2.36-0.14 ± 1.00
Day 572.28 ± 1.471.28 ± 2.06
Day 851.08 ± 1.71-0.90 ± 2.30
Day 127-0.87 ± 1.29-0.89 ± 1.95
Day 169-0.25 ± 1.61-1.51 ± 1.86
SecondaryPercent Change From Baseline in Bone Mineral Density at the One-third Radius

Bone mineral density was assessed using dual energy x-ray absorptiometry (DXA). Scans were analyzed by a central reader.

Time frame:
Baseline and days 29, 57, 85, 127, and 169
Reported as:
Mean · percent change
Percent Change From Baseline in Bone Mineral Density at the One-third Radius
percent changePlaceboRomosozumab
Day 291.715 ± 0.8081.210 ± 0.814
Day 570.832 ± 1.155-0.694 ± 0.827
Day 850.790 ± 1.117-1.941 ± 0.986
Day 127-0.118 ± 1.405-0.439 ± 1.346
Day 1691.866 ± 0.905-0.328 ± 0.702
SecondaryPercent Change From Baseline in Bone Mineral Density at the Total Wrist

Bone mineral density was assessed using dual energy x-ray absorptiometry (DXA). Scans were analyzed by a central reader.

Time frame:
Baseline and days 29, 57, 85, 127, and 169
Reported as:
Mean · percent change
Percent Change From Baseline in Bone Mineral Density at the Total Wrist
percent changePlaceboRomosozumab
Day 291.829 ± 0.617-0.555 ± 0.428
Day 570.940 ± 1.081-1.651 ± 0.574
Day 850.233 ± 0.996-1.690 ± 0.733
Day 1270.001 ± 1.081-0.369 ± 0.765
Day 1690.357 ± 1.237-0.649 ± 0.522
SecondaryPercent Change From Baseline in Bone Mineral Density at the Total Lumbar Spine

Bone mineral density was assessed using dual energy x-ray absorptiometry (DXA). Scans were analyzed by a central reader.

Time frame:
Baseline and days 85 and 169
Reported as:
Mean · percent change
Percent Change From Baseline in Bone Mineral Density at the Total Lumbar Spine
percent changePlaceboRomosozumab
Day 850.345 ± 1.2244.786 ± 0.846
Day 1690.149 ± 0.9057.876 ± 1.351
SecondaryPercent Change From Baseline in Serum Procollagen Type 1 N-terminal Propeptide (P1NP)
Time frame:
Baseline and days 4, 15, 29, 57, 62, 71, 85, 99, 127, and 169
Reported as:
Mean · percent change
Percent Change From Baseline in Serum Procollagen Type 1 N-terminal Propeptide (P1NP)
percent changePlaceboRomosozumab
Day 4-4.40 ± 6.1336.37 ± 10.02
Day 153.46 ± 5.64146.39 ± 20.00
Day 29-0.33 ± 3.44101.85 ± 19.97
Day 57-6.93 ± 4.5274.77 ± 10.91
Day 620.27 ± 9.2092.22 ± 14.71
Day 7119.61 ± 16.22106.91 ± 14.08
Day 8523.83 ± 17.1167.85 ± 19.11
Day 9910.94 ± 15.5717.07 ± 11.79
Day 1275.49 ± 10.2612.56 ± 8.57
Day 16920.85 ± 10.4433.80 ± 13.64
SecondaryPercent Change From Baseline in Serum C-Telopeptide (sCTX)
Time frame:
Baseline and days 4, 15, 29, 57, 62, 71, 85, 99, 127, and 169
Reported as:
Mean · percent change
Percent Change From Baseline in Serum C-Telopeptide (sCTX)
percent changePlaceboRomosozumab
Day 46.62 ± 4.33-23.77 ± 7.78
Day 15-2.29 ± 5.15-33.10 ± 8.85
Day 29-3.19 ± 8.83-21.42 ± 13.98
Day 577.87 ± 6.497.26 ± 16.28
Day 628.69 ± 5.78-12.67 ± 15.15
Day 715.60 ± 5.59-14.72 ± 13.84
Day 85-3.00 ± 7.944.85 ± 19.28
Day 99-9.14 ± 8.1714.29 ± 23.73
Day 127-10.00 ± 8.916.32 ± 16.60
Day 169-3.61 ± 8.9516.06 ± 20.53
SecondaryTime to Maximum Serum Concentration (Tmax) of Romosozumab

Serum concentrations of romosozumab were measured by a validated enzyme-linked immunosorbent assay. The lower limit of quantification (LLOQ) was 50 ng/mL.

Time frame:
First Dose: Day 1 (predose) and on days 4, 15, and 29 (predose). Last Dose: Days 57 (predose), 62, 71, 85, 99, 127, and 169
Reported as:
Median · days
Time to Maximum Serum Concentration (Tmax) of Romosozumab
daysRomosozumab
First dose3.0 (3.0 to 3.0)
Last dose5.0 (5.0 to 14)
SecondaryMaximum Serum Concentration (Cmax) of Romosozumab

Serum concentrations of romosozumab were measured by a validated enzyme-linked immunosorbent assay. The lower limit of quantification (LLOQ) was 50 ng/mL.

Time frame:
First Dose: Day 1 (predose) and on days 4, 15, and 29 (predose). Last Dose: Days 57 (predose), 62, 71, 85, 99, 127, and 169
Reported as:
Mean · μg/mL
Maximum Serum Concentration (Cmax) of Romosozumab
μg/mLRomosozumab
First dose26.8 ± 6.4
Last dose32.3 ± 9.6
SecondaryArea Under the Serum Concentration-time Curve From Time 0 to Tau (AUC0-28)

Serum concentrations of romosozumab were measured by a validated enzyme-linked immunosorbent assay. The lower limit of quantification (LLOQ) was 50 ng/mL. The area under the serum drug concentration-time curve from time zero to tau (tau = 28 days) (AUC0-28) was calculated by the linear trapezoidal method.

Time frame:
First Dose: Day 1 (predose) and on days 4, 15, and 29 (predose). Last Dose: Days 57 (predose), 62, 71, 85, 99, 127, and 169
Reported as:
Mean · μg*day/mL
Area Under the Serum Concentration-time Curve From Time 0 to Tau (AUC0-28)
μg*day/mLRomosozumab
First dose422 ± 75
Last dose501 ± 179
SecondaryArea Under the Serum Concentration-time Curve From Time 0 to Infinity (AUCinf)

Serum concentrations of romosozumab were measured by a validated enzyme-linked immunosorbent assay. The lower limit of quantification (LLOQ) was 50 ng/mL.

Time frame:
Last Dose: Days 57 (predose), 62, 71, 85, 99, 127, and 169
Reported as:
Mean · μg*day/mL
Area Under the Serum Concentration-time Curve From Time 0 to Infinity (AUCinf)
μg*day/mLRomosozumab
Area Under the Serum Concentration-time Curve From Time 0 to Infinity (AUCinf)590 ± 240
SecondaryApparent Clearance (CL/F) of Romosozumab

Serum concentrations of romosozumab were measured by a validated enzyme-linked immunosorbent assay. The lower limit of quantification (LLOQ) was 50 ng/mL.

Time frame:
Last Dose: Days 57 (predose), 62, 71, 85, 99, 127, and 169
Reported as:
Mean · mL/day/kg
Apparent Clearance (CL/F) of Romosozumab
mL/day/kgRomosozumab
Apparent Clearance (CL/F) of Romosozumab5.82 ± 2.12
SecondaryTerminal Half-life (t1/2,z) of Romosozumab

Serum concentrations of romosozumab were measured by a validated enzyme-linked immunosorbent assay. The lower limit of quantification (LLOQ) was 50 ng/mL.

Time frame:
Last Dose: Days 57 (predose), 62, 71, 85, 99, 127, and 169
Reported as:
Mean · days
Terminal Half-life (t1/2,z) of Romosozumab
daysRomosozumab
Terminal Half-life (t1/2,z) of Romosozumab6.82 ± 0.92
SecondaryAccumulation Ratio

Accumulation ratio was calculated as the ratio of AUC0-28 after the last dose to AUC0-28 after the first dose.

Time frame:
First Dose: Day 1 (predose) and on days 4, 15, and 29 (predose). Last Dose: Days 57 (predose), 62, 71, 85, 99, 127, and 169
Reported as:
Mean · ratio
Accumulation Ratio
ratioRomosozumab
Accumulation Ratio1.15 ± 0.27

Adverse events

Collected over 6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1/12 (8.3%)10/12 (83.3%)
Romosozumab—1/12 (8.3%)10/12 (83.3%)
Most frequent serious events
Most frequent serious events
EventPlaceboRomosozumab
Gastrointestinal ulcer haemorrhageGastrointestinal disorders0/121/12
Arthritis infectiveInfections and infestations0/121/12
Cauda equina syndromeNervous system disorders1/120/12
Most frequent other events
Showing 10 of 48
Most frequent other events
EventPlaceboRomosozumab
ArthralgiaMusculoskeletal and connective tissue disorders3/121/12
ConstipationGastrointestinal disorders2/121/12
Injection site reactionGeneral disorders2/121/12
Oedema peripheralGeneral disorders0/122/12
Urinary tract infectionInfections and infestations2/120/12
Musculoskeletal painMusculoskeletal and connective tissue disorders2/121/12
HypertensionVascular disorders2/122/12
AnaemiaBlood and lymphatic system disorders1/120/12
Abdominal distensionGastrointestinal disorders1/120/12
DyspepsiaGastrointestinal disorders1/120/12

Baseline characteristics

All treated participants

Age, Continuous
Age, Continuous(years)PlaceboRomosozumabTotal
Mean62.3 ± 5.665.6 ± 7.263.9 ± 6.5
Age, Customized
Age, Customized(Participants)PlaceboRomosozumabTotal
18 - 64 years9615
65 - 74 years347
≥ 75 years022
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRomosozumabTotal
Female121224
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboRomosozumabTotal
White121224
Polar Moment of Inertia
Polar Moment of Inertia(mm⁴)PlaceboRomosozumabTotal
Median1545.14 (932.79 to 2045.53)1496.50 (1162.51 to 2059.27)1501.96 (932.79 to 2059.27)
08

Study locations

No study locations are listed for this record.

09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2009 to primary completion in Aug 2010, 12 months.

Results were first posted in Jul 2019, 8 years 10 months after primary completion.

Of 13 phase 1 interventional studies under Bone Diseases, Metabolic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 37. This study's 12 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2009
First posted
Aug 3, 2009
StartActual
Aug 18, 2009
Primary completionActual
Aug 19, 2010
CompletionActual
Aug 19, 2010
Results first posted
Jul 5, 2019
Last update
Jul 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00950950
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Aug 3, 2009
Start date
Aug 18, 2009
Primary completion
Aug 19, 2010
Completion
Aug 19, 2010
Results posted
Jul 5, 2019
Last update
Jul 5, 2019

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romosozumab

Start the discussion